Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study.

Authors: Yu J, Xiong A, Wang Q, Chen J, Niu H, Zhou C, Tian P, Zhuang W, Li J, Wang J, Lu J, Gu K, Shi J, Guo J, Di Y, Lv D, Sun D, Cao L, Yang Z, Wu J, Miao L, Pan Y, Li C, Wu X, Yin J, Wang X, Sun M, He M, Cang S, Fang H, Chen P, Zhang M, Yang X, Zhao H, Feng J, Ma X, Hu S, Lu J, Zhao X, Zhuang Z, Sun Y, Sun X, Yu B, Zhu C, Chen J, Xu J, Wang K, Zhou C

Journal: Signal transduction and targeted therapy